Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Self-assembling peptide-based building blocks in medical applications.
Acar H, Srivastava S, Chung EJ, Schnorenberg MR, Barrett JC, LaBelle JL, Tirrell M. Acar H, et al. Among authors: barrett jc. Adv Drug Deliv Rev. 2017 Feb;110-111:65-79. doi: 10.1016/j.addr.2016.08.006. Epub 2016 Aug 14. Adv Drug Deliv Rev. 2017. PMID: 27535485 Free PMC article. Review.
HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer.
Kapil A, Spitzmüller A, Brieu N, Haneder S, Shumilov A, Meier A, Cecchi F, Barkell A, Harder N, Mittermaier K, Hidalgo-Sastre A, Alleze R, Schick M, Schmidt G, Sade H, Tsuchihashi Z, Suto F, Gustavson M, Barrett JC, Carroll D. Kapil A, et al. Among authors: barrett jc. Sci Rep. 2024 May 27;14(1):12129. doi: 10.1038/s41598-024-61957-9. Sci Rep. 2024. PMID: 38802399 Clinical Trial.
The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.
Hardaker EL, Sanseviero E, Karmokar A, Taylor D, Milo M, Michaloglou C, Hughes A, Mai M, King M, Solanki A, Magiera L, Miragaia R, Kar G, Standifer N, Surace M, Gill S, Peter A, Talbot S, Tohumeken S, Fryer H, Mostafa A, Mulgrew K, Lam C, Hoffmann S, Sutton D, Carnevalli L, Calero-Nieto FJ, Jones GN, Pierce AJ, Wilson Z, Campbell D, Nyoni L, Martins CP, Baker T, Serrano de Almeida G, Ramlaoui Z, Bidar A, Phillips B, Boland J, Iyer S, Barrett JC, Loembé AB, Fuchs SY, Duvvuri U, Lou PJ, Nance MA, Gomez Roca CA, Cadogan E, Critichlow SE, Fawell S, Cobbold M, Dean E, Valge-Archer V, Lau A, Gabrilovich DI, Barry ST. Hardaker EL, et al. Among authors: barrett jc. Nat Commun. 2024 Feb 24;15(1):1700. doi: 10.1038/s41467-024-45996-4. Nat Commun. 2024. PMID: 38402224 Free PMC article.
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV. Besse B, et al. Among authors: barrett jc. Nat Med. 2024 Mar;30(3):716-729. doi: 10.1038/s41591-024-02808-y. Epub 2024 Feb 13. Nat Med. 2024. PMID: 38351187 Free PMC article. Clinical Trial.
Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer.
Memon D, Schoenfeld AJ, Ye D, Fromm G, Rizvi H, Zhang X, Keddar MR, Mathew D, Yoo KJ, Qiu J, Lihm J, Miriyala J, Sauter JL, Luo J, Chow A, Bhanot UK, McCarthy C, Vanderbilt CM, Liu C, Abu-Akeel M, Plodkowski AJ, McGranahan N, Łuksza M, Greenbaum BD, Merghoub T, Achour I, Barrett JC, Stewart R, Beltrao P, Schreiber TH, Minn AJ, Miller ML, Hellmann MD. Memon D, et al. Among authors: barrett jc. Cancer Cell. 2024 Feb 12;42(2):209-224.e9. doi: 10.1016/j.ccell.2023.12.013. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215748 Free article.
862 results